Amgen stock toppled Monday after the biotech company's experimental cancer treatment failed to impress investors in a Phase 1 study. The drug attempts to inhibit a protein known as KRAS.

source https://finance.yahoo.com/m/333e573b-3345-392c-af7d-b42645468f9a/amgen-stock-dives-on.html?.tsrc=rss